newsfilter
← Latest News
GlobeNewswire·

Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025 Q3 2026 Vafseo® (vadadustat) net product revenues of